Spyre Therapeutics, Inc. employees and revenue per employee

SYRE · Biotechnology · $8.88B market cap

Spyre Therapeutics, Inc. had 30 employees at the end of fiscal Dec 2023, down 56.5% from a year earlier. Revenue for the year was $886,000, down 62.0% from a year earlier, or $30K per employee. Revenue fell, and headcount fell or held flat with it.

The latest annual report we hold is more than two years old, so these numbers may be out of date.

Employees

30

-56.5% YoY

Revenue

$886,000

-62.0% YoY

Revenue / employee

$30K

Peer median $455K

Rank in industry

99 of 111

Biotechnology

Open roles

5

167 per 1,000 staff

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016
0218436'16'17'18'21'22'23Revenue 19Staff 100

Hover a year for the numbers.

SYRE employees and revenue by fiscal year
Year endingEmployeesRevenuePer employeeStaff YoYRevenue YoY
Dec 202330$886,000$30K-56.5%-62.0%
Dec 202269$2.3M$34K-31.7%-87.6%
Dec 2021101$18.7M$186K——
Dec 201861$3.9M$64K+41.9%-25.3%
Dec 201743$5.2M$121K+43.3%+12.5%
Dec 201630$4.6M$154K——

Open roles on its job board: 5 (167 per 1,000 staff, against its latest annual headcount), as of 2026-11-20. Tracked since 2026-10-03. No 90 day change yet.

Employees, last six fiscal years
30'1643'1761'18101'2169'2230'23
Revenue per employee, last six fiscal years
$154K'16$121K'17$64K'18$186K'21$34K'22$30K'23

Spyre Therapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

CompanyEmployeesRevenueRevenue / employeeShape
SYRE
Spyre Therapeutics, Inc.
30$886,000$30KContracting
CGON
CG Oncology Inc.
142$4.0M$28KEfficient growth
STTK
Shattuck Labs, Inc.
40$1.0M$25KContracting
DNTH
Dianthus Therapeutics, Inc.
92$2.0M$22KHiring into decline
ABSI
Absci Corporation
140$2.8M$20KContracting
INBX
Inhibrx Biosciences Inc.
109$1.3M$12KLeaner
NGNE
Neurogene Inc.
107$925,000$9K—
CLDX
Celldex Therapeutics, Inc.
198$1.5M$8KHiring into decline
ARTV
Artiva Biotherapeutics, Inc.
89$251,000$3K—
Every Healthcare company

Questions about Spyre Therapeutics, Inc.

How many employees does Spyre Therapeutics, Inc. have?
Spyre Therapeutics, Inc. reported 30 employees for the fiscal year ending Dec 2023, in the annual report it filed on February 29, 2024. That is down 56.5% from a year earlier.
What is Spyre Therapeutics, Inc.'s revenue per employee?
Spyre Therapeutics, Inc. brought in $886,000 of revenue in fiscal Dec 2023, which is $30K per employee. That ranks 99 of 111 companies we track in Biotechnology, where the median is $455K.
Is Spyre Therapeutics, Inc. hiring?
Spyre Therapeutics, Inc.'s public job board listed 5 open roles on November 20, 2026, about 167 per 1,000 staff.
Where do these numbers come from?
Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

This page is the filings. The research is a membership.

On the first and third Friday of each month Outpick publishes one stock pick with the full case for owning it, adds it to a live portfolio you can audit, and writes a note when a position closes. A new account gets 21 days of the whole membership with no card, and nothing is charged when it ends.

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

Compare SYRE with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Source: employee counts and revenue as stated in Spyre Therapeutics, Inc.'s annual reports (Form 10-K), latest filed February 29, 2024. This is data, not a recommendation to buy or sell SYRE.